MIRA

Mira Pharmaceuticals Inc

0.6195

Oct 23 • 3:59 PM ET -0.0094 (-1.49%)

0.6207

Aftermarket • 7:29 PM ET +0.0012 (0.19%)

Healthcare Drug Manufacturers - General USA Nano NASD

Oct 22, 8:07 AMMira Pharmaceuticals reports positive 21-day preclinical data showing oral MIRA-55 matches Celebrex pain relief in chronic inflammatory model

Peers: SCLX CRBP SKYE TNXP NRXP ARTL INM ALZN CRDL VRTX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	26.03M
Enterprise Value	17.92M
Income	-31.04M
Sales	0.00M
Book/sh	0.19
Cash/sh	0.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Aug 03, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.19
P/C	3.21
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	200.08
Current Ratio	200.08
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.38
EPS next Y	-0.12
EPS next Q	-0.03
EPS this Y	-
EPS next Y	-
EPS next 5Y	32.70%
EPS past 3/5Y	-41.42% -211.56%
Sales past 3/5Y	- -
EPS Y/Y TTM	-186.73%
Sales Y/Y TTM	-
EPS Q/Q	68.18%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	- -

Insider Own	7.92%
Insider Trans	0.00%
Inst Own	5.51%
Inst Trans	1.23%
ROA	-684.27%
ROE	-710.85%
ROIC	-380.24%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.02%
SMA50	-18.31%
SMA200	-37.27%
Trades

Shs Outstand	42.02M
Shs Float	38.69M
Short Float	1.06%
Short Ratio	0.70
Short Interest	0.41M
52W High	1.79 -65.49%
52W Low	0.60 3.25%
Volatility	7.57% 8.06%
ATR (14)	0.06
RSI (14)	36.76
Beta	1.56
Rel Volume	0.18
Avg Volume	580.94K
Volume	106,232

Perf Week	-2.02%
Perf Month	-26.21%
Perf Quarter	-29.76%
Perf Half Y	-41.00%
Perf YTD	-58.97%
Perf Year	-60.03%
Perf 3Y	-77.22%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	6.50
Prev Close	0.63
Price	0.62
Change %	-1.49%

Oct-22-26 08:00AM	MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study (GlobeNewswire) -7.76%
Sep-17-26 08:30AM	MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review (GlobeNewswire) +5.52%
Sep-01-26 08:00AM	MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND (GlobeNewswire) +11.66%
Aug-06-26 08:00AM	MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 (GlobeNewswire)
Jul-30-26 08:00AM	MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies (GlobeNewswire)
08:00AM	Loading…
Jul-10-26 08:00AM	MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain (ACCESSWIRE)
Jul-06-26 09:00AM	MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction (ACCESSWIRE)
Jun-25-26 08:15AM	MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC (ACCESSWIRE)
Jun-17-26 08:00AM	MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy (ACCESSWIRE)
Jun-04-26 08:00AM	MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 (ACCESSWIRE)
May-27-26 08:00AM	MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN (ACCESSWIRE) +18.58%
May-19-26 08:20AM	Tapestry patents AI data analytics tech (Retail Dive)
May-14-26 08:00AM	MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 (ACCESSWIRE)
May-13-26 08:00AM	MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate (ACCESSWIRE)
Mar-23-26 09:00AM	MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies (ACCESSWIRE) +22.28%
08:00AM	Loading…
Mar-04-26 08:00AM	MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 (ACCESSWIRE)
Feb-08-26 03:50PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-03-26 07:30AM	MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study (ACCESSWIRE)
Nov-19-25 03:01PM	EXCLUSIVE: 'We Dropped Out Of Harvard And Dedicated Our Lives To Building This'Their $349 AI With 'Hyper-Intelligent' Brain Rivals Meta (Benzinga)
Nov-02-25 04:32PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-24-25 07:30AM	MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication (ACCESSWIRE)
Oct-16-25 07:30AM	MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain (ACCESSWIRE) +36.36%
Sep-30-25 07:30AM	MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction (ACCESSWIRE)
Sep-22-25 08:00AM	MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog (ACCESSWIRE) +6.40%
Sep-16-25 07:30AM	MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals (ACCESSWIRE) -5.07%
Sep-12-25 07:30AM	MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation (ACCESSWIRE) -12.65%
Aug-19-25 08:30AM	MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage (ACCESSWIRE)
Aug-12-25 08:30AM	MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin (ACCESSWIRE)
Jul-30-25 07:30AM	MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study (ACCESSWIRE)
Jul-29-25 07:30AM	MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain (ACCESSWIRE)
02:35PM	Loading…
Jul-13-25 02:35PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-11-25 08:00AM	MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition (ACCESSWIRE) +6.67%
Jul-03-25 08:00AM	MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks (ACCESSWIRE)
Jun-30-25 08:00AM	MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition (ACCESSWIRE)
07:20AM	EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study (Benzinga)
Jun-25-25 08:00AM	MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects (ACCESSWIRE)
Jun-18-25 08:30AM	MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology (ACCESSWIRE)
May-28-25 08:30AM	MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program (ACCESSWIRE) +6.35%
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 08:00AM	MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review (ACCESSWIRE) +7.76%
07:16AM	EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million (Benzinga)
May-06-25 08:00AM	MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity (ACCESSWIRE)
07:16AM	EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study (Benzinga)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
Apr-23-25 08:00AM	MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation (ACCESSWIRE) +7.08%
Apr-16-25 08:00AM	MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion (ACCESSWIRE) +19.26%
07:15AM	EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study (Benzinga)
Apr-02-25 08:37AM	Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2 (TipRanks)
Apr-01-25 08:00AM	MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain (ACCESSWIRE)
Mar-25-25 09:00AM	Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit (TipRanks)
Mar-24-25 07:30AM	MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development (ACCESSWIRE)
07:16AM	EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug (Benzinga)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks) -5.60%
Mar-13-25 08:00AM	MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain (ACCESSWIRE) +25.00%
Mar-04-25 08:00AM	MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain (ACCESSWIRE)
07:45AM	EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain (Benzinga)
Dec-27-24 02:56AM	Memecoin Degens Raise Millions for Rare Cancer Research After a Fathers Plea (CoinDesk)
Dec-19-24 09:00AM	MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development (ACCESSWIRE)
08:25AM	EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment (Benzinga)
Dec-10-24 08:30AM	MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End (ACCESSWIRE)
08:15AM	EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain (Benzinga)
Nov-20-24 07:44AM	MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site (ACCESSWIRE) -9.64%
Oct-29-24 10:57AM	MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials (GuruFocus.com) +10.19%
Oct-28-24 01:41PM	MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain (Benzinga) +21.71%
07:30AM	MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain (ACCESSWIRE)
Oct-27-24 05:34PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024 (Market Exclusive)
Oct-21-24 07:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study (ACCESSWIRE)
Sep-27-24 07:30AM	MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 (ACCESSWIRE) +8.41%
Sep-19-24 09:00AM	MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 (News Direct)
Sep-18-24 07:00AM	MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 (ACCESSWIRE) -10.69%
Sep-11-24 07:30AM	MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA (ACCESSWIRE) +9.30%
Aug-26-24 08:00AM	MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study (ACCESSWIRE) +14.05%
Aug-19-24 07:30AM	MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End (ACCESSWIRE) -7.77%
Aug-12-24 08:30AM	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman (GlobeNewswire)
08:00AM	MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor (ACCESSWIRE)
Aug-05-24 09:40AM	PayPal, Kellanova upgraded: Wall Street's top analyst calls (The Fly)
Jul-25-24 03:24PM	Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data (Benzinga) +28.81%
07:00AM	MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action (ACCESSWIRE)
Jul-22-24 12:56PM	Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? (InvestorPlace) +627.35%
10:31AM	Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders (Benzinga)
08:00AM	MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance (ACCESSWIRE)
Jul-15-24 07:00AM	Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC (ACCESSWIRE) +25.59%
Jun-24-24 08:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing (PR Newswire)
Jun-10-24 08:30AM	Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year (PR Newswire)
May-29-24 08:45AM	Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance (PR Newswire)
May-21-24 08:45AM	MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog (PR Newswire) +20.00%
May-20-24 08:00AM	Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog (PR Newswire) +29.77%
May-13-24 09:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
Apr-02-24 08:00AM	Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission (PR Newswire)
Apr-01-24 02:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-21-24 11:04AM	MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor (PR Newswire)
Mar-08-24 08:19AM	Why Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today? (InvestorPlace) +65.28%
Feb-05-24 08:30AM	MIRA Pharmaceuticals Provides Corporate Update (PR Newswire) +45.99%
Dec-04-23 08:00AM	MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations (PR Newswire) -5.26%
Nov-29-23 08:00AM	MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% (PR Newswire)
Nov-21-23 10:42AM	MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time (PR Newswire) -16.13%
10:09AM	MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a (PR Newswire)
Nov-20-23 08:00AM	MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 (PR Newswire) +40.06%
Oct-26-23 07:23AM	MIRA: Developing Cannabis with Benefits and Without Side Effects (Zacks) +5.38%

Show Previous News

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

CEO & ChairmanMr. Erez Aminov

Chief Financial OfficerMr. Andriy Mushak CPA

Chief Scientific AdvisorDr. Itzchak Angel Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIRA

Mira Pharmaceuticals Inc

Upgrade your Finviz experience